Business
Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
- Valbenazine Met the Primary Endpoint of Significant
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"- Valbenazine Met the Primary Endpoint of Significant (p","length":77,"tagName":"div"}]